Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Biotechnology Value Fund
AddedFeb 13, 2024
UpdatedJun 28, 2026
Biotechnology Value Fund

Biotechnology Value Fund

Operating

BVF: A San Francisco-based private investment firm specializing in long-term biotechnology investments.

Location
San Francisco, CA, US
Founded
1993
Firm
Compare
Portfolio
Employees
Website

Investments

Septerna
Septerna

Total Raised

$250M

Rounds

2

Series B$150MJuly 2023
Series A$100MJanuary 2022
Crossbow Therapeutics
Crossbow Therapeutics
Series B

Total Raised

$157M

Rounds

2

Series A$80MJuly 2023
Quanta Therapeutics
Quanta Therapeutics

Total Raised

$140.7M

Rounds

4

Series D$50.7MMay 2023
Series C$60MOctober 2021
Delcath Systems
Delcath Systems
Public

Total Raised

$269.6M

Rounds

13

Post Ipo Equity$85MMarch 2023
Unicycive Therapeutics
Unicycive Therapeutics
Public

Total Raised

$36.6M

Rounds

4

Post Ipo Equity$30MMarch 2023
Verastem
Verastem
Public

Total Raised

$280M

Rounds

9

Post Ipo Equity$60MJanuary 2023
Palvella Therapeutics
Palvella Therapeutics
Acquired

Total Raised

$106.8M

Rounds

6

Series D$37.7MJanuary 2023
Nimbus Therapeutics
Nimbus Therapeutics
Public

Total Raised

$637M

Rounds

9

Late Stage Private$125MSeptember 2022
Series Unknown$105MJuly 2021
Autobahn Therapeutics
Autobahn Therapeutics

Total Raised

$108.7M

Rounds

2

Series Unknown$32.7MSeptember 2022
Kymera Therapeutics
Kymera Therapeutics
Public

Total Raised

$879M

Rounds

8

Post Ipo Equity$150MAugust 2022
Dren Bio
Dren Bio

Total Raised

$130.1M

Rounds

4

Series B$65MJune 2022
Elektrofi
Elektrofi

Total Raised

$41.9M

Rounds

3

Series B$40MJune 2022
Plexium
Plexium

Total Raised

$165M

Rounds

6

Series B$102MFebruary 2022
Ventus Therapeutics
Ventus Therapeutics

Total Raised

$370.1M

Rounds

5

Series C$140MFebruary 2022
Simcha Therapeutics
Simcha Therapeutics

Total Raised

$65M

Rounds

2

Series B$40MJanuary 2022
Shoreline Biosciences
Shoreline Biosciences

Total Raised

$186M

Rounds

3

Series B$140MNovember 2021
Exo Therapeutics
Exo Therapeutics

Total Raised

$103M

Rounds

2

Series B$78MOctober 2021
Alpine Immune Sciences
Alpine Immune Sciences
Acquired

Total Raised

$475.3M

Rounds

8

Post Ipo Equity$91MSeptember 2021
Whitehawk Therapeutics
Whitehawk Therapeutics
Public

Total Raised

$250.5M

Rounds

4

Post Ipo Equity$155MAugust 2021
Numab
Numab

Total Raised

$122M

Rounds

3

Series C$100MMay 2021
Janux Therapeutics
Janux Therapeutics
Public

Total Raised

$252.4M

Rounds

5

Series B$125MApril 2021
AltruBio
AltruBio

Total Raised

$102.6M

Rounds

4

Series A$63MApril 2021